Wellington The board Gathering LLP Lifts Stake in Agios Drugs, Inc. (NASDAQ:AGIO)

Wellington The board Gathering LLP Lifts Stake in Agios Drugs, Inc. (NASDAQ:AGIO)

Wellington The board Gathering LLP lifted its property in Agios Drugs, Inc.

4.8% during the first quarter, as per the organization in its latest Structure 13F recording with the Protections and Trade Commission. The institutional financial backer claimed 5,723,131 portions of the biopharmaceutical organization’s stock subsequent to purchasing 260,474 extra offers during the period. Wellington The executives Gathering LLP possessed roughly 10.30% of Agios Drugs worth $131,460,000 as of its latest recording with the Protections and Trade Commission.

A few other mutual funds and other institutional financial backers have likewise as of late changed their possessions of the business. Vanguard Gathering Inc. lifted its stake in portions of Agios Drugs by 0.4% in the second from last quarter. Vanguard Gathering Inc.

image 4

presently claims 5,225,097 portions of the biopharmaceutical organization’s stock worth $147,766,000 in the wake of purchasing 21,396 extra offers in the last quarter. State Road Corp brought its stake up in Agios Drugs by 6.7% during the subsequent quarter.

image 5

State Road Corp currently claims 3,401,219 portions of the biopharmaceutical organization’s stock worth $75,405,000 subsequent to buying 214,706 extra offers during the period. Truce Capital LLC brought its stake up in Agios Drugs by 42.9% during the final quarter. Cease-fire Capital LLC currently possesses 2,750,000 portions of the biopharmaceutical organization’s stock worth $77,220,000 in the wake of buying 826,000 extra offers during the period. Layered Asset Consultants LP brought its stake up in Agios Drugs by 11.8% during the final quarter. L

image 6

ayered Asset Counselors LP currently claims 1,653,079 portions of the biopharmaceutical organization’s stock worth $46,417,000 in the wake of buying 174,690 extra offers during the period. At last, First Trust Consultants LP brought its stake up in Agios Drugs by 27.2% during the primary quarter. First Trust Counsels LP presently possesses 1,613,429 portions of the biopharmaceutical organization’s stock worth $46,967,000 subsequent to buying 344,959 extra offers during the period.

opened at $28.17 on Monday. The organization’s multi day straightforward moving normal is $26.96 and its 200-day basic moving normal is $25.31. The organization has a market capitalization of $1.57 billion, a cost to-profit proportion of – 7.41 and a beta of 0.96. Agios Drugs, Inc. has a 1 year low of $21.07 and a 1 year high of $34.76.

last delivered its quarterly income results on Thursday, August third. The biopharmaceutical organization announced ($1.51) profit per share (EPS) for the quarter, beating investigators’ agreement appraisals of ($1.60) by $0.09. The business had income of $6.70 million for the quarter, contrasted with the agreement gauge of $6.46 million. Agios Drugs had a negative net edge of 1,042.56% and a negative profit from value of 20.24%. The business’ income was up 20.1% on a year-over-year premise. During a similar period in the earlier year, the firm procured ($1.68) EPS. Values investigators anticipate that Agios Drugs, Inc. will post – 6.29 profit per share for the ongoing year.

Examiners Set New Value Targets
Various values experts have remarked on AGIO shares. JPMorgan Pursue and Co. scaled down their objective cost on portions of Agios Drugs from $33.00 to $32.00 and set a “nonpartisan” rating on the stock in an exploration note on Monday, August seventh

begun inclusion on portions of Agios Drugs in an exploration note on Thursday, August seventeenth. They set a “sell” rating on the stock. One examiner has evaluated the stock with a sell rating, two have given a hold rating and two have doled out a purchase rating to the stock. As indicated by MarketBeat, Agios Drugs at present has a typical rating of “Hold” and an agreement target cost of $36.00.

Insider Movement
Elsewhere in the world, insider Theodore James Jr. Washburn sold 1,232 portions of the business’ stock in an exchange that happened on Tuesday, August first. The offers were sold at a typical cost of $26.26, for a complete worth of $32,352.32. Following the deal, the insider presently straightforwardly claims 5,659 portions of the organization’s stock, esteemed at around $148,605.34. The exchange was unveiled in a lawful recording with the Protections and Trade Commission, which is accessible through

In related news, insider Theodore James Jr. Washburn sold 1,232 portions of Agios Drugs stock in an exchange that happened on Tuesday, August first. The offers were sold at a typical cost of $26.26, for a complete worth of $32,352.32. Following the fruition of the exchange, the insider presently possesses 5,659 offers in the organization, esteemed at $148,605.34. The deal was uncovered in a record documented with the Protections and Trade Commission, which is accessible

Likewise, Chief Kaye I. Cultivate Cheek sold 25,000 portions of Agios Drugs stock in an exchange that happened on Wednesday, August ninth. The offers were sold at a typical cost of $25.96, for a complete exchange of $649,000.00. Following the fulfillment of the exchange, the chief currently possesses 11,524 portions of the organization’s stock, esteemed at around $299,163.04. The revelation for this deal can be found

Over the most recent three months, insiders have sold 61,016 portions of organization stock esteemed at $1,645,859. Organization insiders own 4.24% of the organization’s stock.

Agios Drugs, Inc, a biopharmaceutical organization, takes part in the revelation and improvement of medications in the field of cell digestion. The organization creates PYRUKYND (mitapivat), an activator of wild-type and freak pyruvate kinase (PK), chemicals for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic condition and hemolytic anemias.

MarketBeat monitors Money Road’s top of the line and best carrying out groundwork experts and the stocks they prescribe to their clients consistently. MarketBeat has identifiedtop experts are discreetly murmuring to their clients to purchase now before the more extensive market gets on… what’s more, Agios Drugs wasn’t on the rundown.

While Agios Drugs right now has a “Moderate Purchase” rating among examiners, first class investigators accept these five stocks are better purchases.

Leave a Comment

0Shares